Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Novartis
GlaxoSmithKline
Orca Biosystems, Inc.
Novartis
Novartis
Takeda
Swedish Orphan Biovitrum
Cogent Biosciences, Inc.
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Ionis Pharmaceuticals, Inc.
Novartis
Incyte Corporation
Incyte Corporation
Taiho Oncology, Inc.
Incyte Corporation
TC Biopharm
Ryvu Therapeutics SA
Blueprint Medicines Corporation
Ryvu Therapeutics SA
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
PharmaEssentia Japan K.K.
Novartis
Novartis
Incyte Corporation
PharmaEssentia
Protagonist Therapeutics, Inc.
PharmaEssentia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Cogent Biosciences, Inc.
GCP-Service International West GmbH
Italfarmaco
Blueprint Medicines Corporation
Novartis
Otsuka Beijing Research Institute
Aprea Therapeutics
GCP-Service International West GmbH
Ascentage Pharma Group Inc.
LEO Pharma
Shenzhen TargetRx Co., Ltd.
Syros Pharmaceuticals
Ensoma
Astellas Pharma Inc
GlaxoSmithKline
Astex Pharmaceuticals, Inc.
Telios Pharma, Inc.
Incyte Corporation
Protagonist Therapeutics, Inc.
Keros Therapeutics, Inc.